目前治疗中风的神经保护剂。

IF 1.1 4区医学 Q3 REHABILITATION

Turkish Journal of Physical Medicine and Rehabilitation Pub Date : 2024-05-16 eCollection Date: 2024-06-01 DOI:10.5606/tftrd.2024.15287

Tuğra Yanık, Burcu Yanık

{"title":"目前治疗中风的神经保护剂。","authors":"Tuğra Yanık, Burcu Yanık","doi":"10.5606/tftrd.2024.15287","DOIUrl":null,"url":null,"abstract":"What is expected from neuroprotection is to inhibit neuronal death and halt or decelerate the neuronal loss to lower the mortality rates, decrease disability, and improve the quality of life following an acute ischemic stroke. Several agents were described as neuroprotective up to date; however, there is still debate which to use in the neurorehabilitation of stroke patients, in terms of both efficacy and also safety. In this review, we discuss the agents, citicoline, cerebrolysin and MLC901 (NeuroAiD II), the three agents which have started to be used frequently in neurorehabilitation clinics recently in the light of the current literature.","PeriodicalId":56043,"journal":{"name":"Turkish Journal of Physical Medicine and Rehabilitation","volume":"70 2","pages":"157-163"},"PeriodicalIF":1.1000,"publicationDate":"2024-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11209336/pdf/","citationCount":"0","resultStr":"{\"title\":\"Current neuroprotective agents in stroke.\",\"authors\":\"Tuğra Yanık, Burcu Yanık\",\"doi\":\"10.5606/tftrd.2024.15287\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"What is expected from neuroprotection is to inhibit neuronal death and halt or decelerate the neuronal loss to lower the mortality rates, decrease disability, and improve the quality of life following an acute ischemic stroke. Several agents were described as neuroprotective up to date; however, there is still debate which to use in the neurorehabilitation of stroke patients, in terms of both efficacy and also safety. In this review, we discuss the agents, citicoline, cerebrolysin and MLC901 (NeuroAiD II), the three agents which have started to be used frequently in neurorehabilitation clinics recently in the light of the current literature.\",\"PeriodicalId\":56043,\"journal\":{\"name\":\"Turkish Journal of Physical Medicine and Rehabilitation\",\"volume\":\"70 2\",\"pages\":\"157-163\"},\"PeriodicalIF\":1.1000,\"publicationDate\":\"2024-05-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11209336/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Turkish Journal of Physical Medicine and Rehabilitation\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.5606/tftrd.2024.15287\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/6/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q3\",\"JCRName\":\"REHABILITATION\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Turkish Journal of Physical Medicine and Rehabilitation","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5606/tftrd.2024.15287","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/6/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"REHABILITATION","Score":null,"Total":0}

引用次数: 0

摘要

神经保护的预期目标是抑制神经元死亡，阻止或减缓神经元损失，从而降低急性缺血性中风后的死亡率，减少残疾，提高生活质量。迄今为止，已有多种药物被描述为具有神经保护作用；然而，在脑卒中患者的神经康复中使用哪种药物在疗效和安全性方面仍存在争议。在这篇综述中，我们将讨论柠檬胆碱、脑溶酶和 MLC901（NeuroAiD II）这三种药物，根据目前的文献资料，这三种药物最近开始在神经康复诊所频繁使用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Current neuroprotective agents in stroke.

What is expected from neuroprotection is to inhibit neuronal death and halt or decelerate the neuronal loss to lower the mortality rates, decrease disability, and improve the quality of life following an acute ischemic stroke. Several agents were described as neuroprotective up to date; however, there is still debate which to use in the neurorehabilitation of stroke patients, in terms of both efficacy and also safety. In this review, we discuss the agents, citicoline, cerebrolysin and MLC901 (NeuroAiD II), the three agents which have started to be used frequently in neurorehabilitation clinics recently in the light of the current literature.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Turkish Journal of Physical Medicine and Rehabilitation Health Professions-Physical Therapy, Sports Therapy and Rehabilitation

CiteScore

2.20

自引率

0.00%

发文量

期刊介绍： The Turkish Journal of Physical Medicine and Rehabilitation (Formerly published as Türkiye Fiziksel Tıp ve Rehabilitasyon Dergisi) is the official journal of the Turkish Society of Physical Medicine and Rehabilitation. The journal is an international open-access, double-blind peer-reviewed periodical journal bringing the latest developments in all aspects of physical medicine and rehabilitation, and related fields. The journal publishes original articles, review articles, editorials, case reports (limited), letters to the editors. The target readership includes academic members, specialists, residents working in the fields of Physical Medicine and Rehabilitation. The language of the journal is English and it is published quarterly (in March, June, September, and December).